Abstract
We aimed to identify the effects of intraoperative applied leukocyte-poor platelet-rich plasma (LP-PRP) during knee arthroscopy for degenerative lesions involving pain, function and quality of life. We performed a randomized controlled, double-blind trial (RCT) including 58 patients for arthroscopic knee surgery for cartilage or meniscal degeneration with allocation into the LP-PRP (n=24) or control group (n=34). During arthroscopy, LP-PRP was injected intra-articular in the intervention group. At baseline, 6weeks, 6months and 12months pain, function, and life quality were assessed. 91% of enrolled patients were available for 12months follow-up. Pain was significantly lower in the LP-PRP group (VAS 0.9. vs. 2.3) at 6 (p=0.008) but not at 12months (VAS 1.0 vs. 1.6, p=0.063). LP-PRP application improved the Lysholm Score at 6 (77.5 vs. 65.6, p=0.033) and 12months (83.2 vs.70.0, p=0.007). Assessment of life quality (SF-36) concerning the physical component summary was significantly higher at 6weeks (33.9 vs. 25.6, p=0.001) and 6months (29.9 vs. 27.1, p=0.027) in the LP-PRP group but equal at 1year (31.4 vs. 30.1, p=0.438). Intraoperative application of LP-PRP may enhance pain reduction and gain of knee function within 6-12months compared to arthroscopy alone. II, randomized controlled clinical trial with reduced power. CLINICALTRIALS. NCT02189408.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
